Date: 2015-12-04
Type of information: Nomination
Compound:
Company: Reneuron (UK)
Therapeutic area: Regenerative Medicine
Type agreement: nomination
Action mechanism:
Disease:
Details: * On December 4, 2015, ReNeuron, a UK-based stem cell therapy development company, announced the appointment of Dr Mike Owen as a Non-executive Director of the Company with immediate effect. He will also chair the Company’s Scientific Advisory Board.
Dr Owen was formerly Senior Vice President for Biopharmaceuticals Research at GSK where he was responsible for the discovery and development of antibody drugs in multiple therapeutic areas through to successful clinical proof of concept. He was also a Founder and Chief Scientific Officer of Kymab Ltd, an antibody-based biotech company, and for many years held a research position at the Imperial Cancer Research Fund (now CR-UK). He currently serves as a director of Zealand Pharma, Ossianix Inc, BliNK
Biomedical SAS and Avacta plc and is a member of the Scientific Advisory Boards of Kymab Ltd and the CRT Pioneer Fund LP, and the investor advisory board of HS Lifesciences gmbh. He is a Fellow of the Academy of Medical Sciences and a member of the European Molecular Biology Organisation.
Financial terms:
Latest news:
